Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 12/20 | 0.34 |
| ▸ | TP53 | P04637 | 10/20 | 0.34 |
| ▸ | MME | P08473 | 2/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29813546 | 0.84 | MDM2 (0.32) | MDM2TP53MMEACEFFAR4 | |
| SCHEMBL20597918 | 0.84 | MDM2 (0.32) | MDM2TP53MMEACEFFAR4 | |
| SCHEMBL19376972 | 0.84 | MDM2 (0.32) | MDM2TP53MMEACEFFAR4 | |
| SCHEMBL19355012 | 0.84 | MDM2 (0.32) | MDM2TP53MMEACEFFAR4 | |
| SCHEMBL19331576 | 0.82 | FFAR4 (0.35) | MDM2TP53MMEACEFFAR4 | |
| SCHEMBL19331562 | 0.75 | FFAR4 (0.33) | MDM2TP53MMEACEFFAR4 | |
| SCHEMBL19376942 | 0.73 | FFAR4 (0.35) | MDM2TP53MMEACEFFAR4 | |
| SCHEMBL19331594 | 0.73 | FFAR4 (0.35) | MDM2TP53MMEACEFFAR4 | |
| SCHEMBL19376969 | 0.73 | PAK1 (0.35) | MDM2TP53MMEACEFFAR4 | |
| SCHEMBL29813676 | 0.73 | PAK1 (0.35) | MDM2TP53MMEACEFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157061-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157061-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | MDM2 2102/4885TP53 3917/4885MME 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.